Quixgen, Inc.

Merck Sharp + Dohme Corp.

Hong-Ping Guan

Yusheng Xiong

Wenjun Huang

Songnian Lin

Harry R Davis

Jose M Castro-Perez

Thomas P Roddy

Liangsu Wang

Samuel E Engel

Sheng-Ping Wang

Samuel S Engel

Douglas G Johns

Stephen F Previs

Steven F Previs

Provided herein are spirolactone compounds of Formula I that are useful as inhibitors of ACC1 and/or ACC2. The spirolactone compounds described herein can be used for treating a disease or disorder associated with aberrant ACC1 and/or ACC2 activities, for example, non-alcoholic steatohepatitis (NASH), acne, obesity, diabetes, and cancer. Also provided herein are pharmaceutical compositions comprising the spirolactone compound of Formula I, or pharmaceutically acceptable salt thereof.

Spirolactone compounds

Provided herein are spirolactone compounds of Formula I that are useful as inhibitors of ACC1 and/or ACC2. The spirolactone compounds described herein can be used for treating a disease or disorder associated with aberrant ACC1 and/or ACC2 activities, for example, non-alcoholic steatohepatitis (NASH), acne, obesity, diabetes, and cancer. Also provided herein are pharmaceutical compositions comprising the spirolactone compound of Formula I, or pharmaceutically acceptable salt thereof. 

Use of a glucagon receptor antagonist in combination with a cholesterol absorption inhibitor for the treatment of diabetes and related conditions is disclosed.

Methods of treating diabetes by administering a glucagon receptor antagonist in combination with a cholesterol absorption inhibitor

Growing community of inventors

Scotch Plains, NJ, United States of America

Hong-Ping Guan